Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican) and early elimination of cyclosporine (Sandimmun Neoral) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy

Next Previous
Trial Profile

A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican) and early elimination of cyclosporine (Sandimmun Neoral) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Antithymocyte globulin; Ciclosporin; Corticosteroids; Mycophenolate mofetil
  • Indications Heart transplant rejection
  • Focus Therapeutic Use
  • Acronyms SCHEDULE
  • Sponsors Novartis Healthcare; Novartis Norge; Novartis Pharmaceuticals

Most Recent Events

  • 06 Apr 2019 Results of the substudy assessing the association between mild ACR within 1 year of heart transplantation and development of CAV at 3 years post heart transplantation, presented at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
  • 12 Mar 2019 Results published in the Transplantation
  • 14 Apr 2018 Results of 3 years follow up assessing the effect of everolimus vs calcineurin inhibitors on left ventricular mass in heart transplant patients presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top